Figure 1a Principal Component Analysis



Figure 1b Hierarchical Cluster Analysis



Figure 2 Classification Accuracy

accuracy	t(15;17) - t(8;21)	t(15;17) - inv(16)	inv(16) - t(8;21)	t(8;21) - R	t(15;17) - R	inv(16) - R
U78556						1.00
M98539					1.00	
Y07846				1.00		
M63582				1.00		
N90866		1.00				
J03853			1.00	1.00		
M26326	1,00			1.00		
L20433			1.00	1.00		
X64624	1.00		1.00	1.00		
N99340			1.00			1.00
M81141	1.00				1.00	
AF013570			1.00			1.00
AI207842		1.00			1.00	1.00
D87433	1.00			1.00		
X00457	1.00					
X96719		1,00			1.00	
AF013611	1,00			1.00		
AF001548			1.00			1.00


PCA of AML data based on 312 genes (diff'tial between 3 classes)
first principal component
second principal component
-10
0
10
20
-10
0
10
20
M2
M3
M4eo

Figure 3a



Figure 3b1


37747_at
35016_at
34210_at
37039_at
31886_at
38096_f_at
359_at
37283_at
41273_at
34519_at
35766_at
38095_i_at
36253_at
1385_at
32747_at

Figure 3b2



Figure 4

Decision trees according to IE

5a) Pairwise Comparison of Normal BM and AML

<u>Significance Analysis of Microarrays</u>:
Selection of 127 differentially expressed genes based on a permutation test (K-Nearest Neighbour Imputer)



5b) Principal Component Analysis

based on 127 significantly differentially expressed genes as selected by SAM = Significance Analysis of Microarrays

2-dimensional



3-dimensional



AML	=	acute myeloid leukemia, n = 48
normal BM	=	bone marrow from healthy volunteers, n = 8

5c) Hierarchical Cluster Analysis



6a) Pairwise Comparison of Normal BM and ALL

<u>Significance Analysis of Microarrays</u>:
Selection of 186 differentially expressed genes based on a permutation test (K-Nearest Neighbour Imputer)



6b) Principal Component Analysis

based on 186 significantly differentially expressed genes as selected by SAM = Significance Analysis of Microarrays

2-dimensional



3-dimensional



ALL = akute lymphoblastic leukemia, n = 9
normal BM = bone marrow from healthy volunteers, n =8

6c) Hierarchical Cluster Analysis



7a) Pairwise Comparison of Normal BM and CML

<u>Significance Analysis of Microarrays</u>:
Selection of 162 differentially expressed genes based on a permutation test (K-Nearest Neighbour Imputer)



7b) Principal Component Analysis

based on 200 significantly differentially expressed genes as selected by SAM = Significance Analysis of Microarrays

2-dimensional



3-dimensional



CML	=	chronic myeloid leukemia, n = 8
normal BM	=	bone marrow from healthy volunteers, n =8

7c) Hierarchical Cluster Analysis



8a) Pairwise Comparison of Normal BM and CLL

<u>Significance Analysis of Microarrays</u>:
Selection of 200 differentially expressed genes based on a permutation test (K-Nearest Neighbor Imputer)



8b) Principal Component Analysis

based on 200 significantly differentially expressed genes as selected by SAM = Significance Analysis of Microarrays

2-dimensional *3-dimensional*



CLL = chronic lymphatic leukemia, n = 7

normal BM = bone marrow from healthy volunteers, n =8

8c) Hierachical Cluster Analysis



9a) AML-WHO Classification

Significance Analysis of Microarrays:
Selection of 124 differentially expressed genes based on a permutation test (K-Nearest Neighbor Imputer)



9b) Principal Component Analysis

based on 124 significantly differentially expressed genes as selected by SAM = Significance Analysis of Microarrays

2-dimensional *3-dimensional*



AML = 4 distinct cytogenetic subgroups, n = 48

normal BM = bone marrow from healthy volunteers, n =8

9c) Hierachical Cluster Analysis



10a) Comparison of Normal BM versus Leukemia

<u>Significance Analysis of Microarrays</u>:
Selection of Top100 differentially expressed genes based on a permutation test (K-Nearest Neighbour Imputer)



10b) Principal Component Analysis

based on 100 significantly differentially expressed genes as selected by SAM = Significance Analysis of Microarrays

2-dimensional *3-dimensional*



leukemia = 4 entities: AML, ALL, CML, CLL, n = 72
normal BM = bone marrow from healthy volunteers, n =8

10c) Hierachical Cluster Analysis




1st step
CLL
CML
nBM
ALL
AML
2nd step
t(9;22)
t(11q23)/MLL
t(8;14)
T-ALL
t(8;21)
t(11q23)/MLL
t(15;17)
inv(16)
'other'

Figure 11a


AML subgroups
normal karyotype
complex aberrant
trisomy 8 sole
other
t(11q23)/MLL
inv(16)
t(8;21)
t(15;17)
POU4F1
HOXB5
STATI2*
CBFA2T1
ECM1
MYH11
MYH11
TRH
CTSW
STAB1*
LAMB2
CACNA2D2
POU2F2
PRDX4
ARHGAP4
HLA-DPA1
RGS10
SELL
CDK2AP1
COPEB
B4-2*
CD81
MBNL
ETFB
RABGGTA

Figure 11b


ALL subgroups
t(11q23)/MLL
t(9;22)
t(8;14)
T-ALL
VLDLR
CTFG
CD3D
MME
unknown*
KIAA0870*
MONDOA*
HELO1
ADA
MYB
MYB
FLJ12443*
CTNNA1
CTNNA1
SCYA3
LYN
TRB
SIT*
ANXA5

Figure 11c

Figure 12a


INV16-
MEAN inv16
MEAN (non INV16)
101.3
10.0
myosin, heavy polypeptide 11, smooth muscle
INV16-OTHER
MEAN inv16
MEAN OTHER
148.8
11.0
myosin, heavy polypeptide 11, smooth muscle
INV16-OTHER
MEAN inv16
MEAN OTHER
44.4
6.6
extracellular matrix protein 1
INV16-
MEAN inv16
MEAN (non INV16)
148.8
11.6
myosin, heavy polypeptide 11, smooth muscle
INV16-t1517
MEAN inv16
MEAN t1517
140.9
major histocompatibility complex, class II, DP alpha 1
INV16-T821
MEAN inv16
MEAN t821
148.8
12.1
myosin, heavy polypeptide 11, smooth muscle
INV16-t821
MEAN inv16
MEAN t821
131.4
59.1
CDK2-associated protein 1
INV16-t1517
MEAN inv16
MEAN t1517
735.2
53.4
selectin L (lymphocyte adhesion molecule 1)

Figure 12b


MLL-INV16
MEAN MLL
MEAN inv16
40.6
8.7
laminin, beta 2 (laminin S)
MLL-INV16
730.4
168.2
CD81 antigen (target of antiproliferative antibody 1)
MLL-t821
MEAN MLL
MEAN t821
162.7
27.3
electron-transfer-flavoprotein, beta polypeptide
MLL-t1517
MEAN MLL
MEAN t1517
145.8
17.4
peroxiredoxin 4
MLL-OTHER
MEAN MLL
MEAN OTHER
120.8
74.2
Rab geranylgeranyltransferase, alpha subunit
MLL-OTHER
44.4
104.0
proline-rich protein with nuclear targeting signal
MLL-OTHER
390.2
1031.5
core promoter element binding protein
MLL-OTHER
56.7
21.8
POU domain, class 2, transcription factor 2
MLL-
MEAN MLL
MEAN (non-MLL)
274.0
113.7
muscleblind (Drosophila)-like
MLL-
139.1
82.3
electron-transfer-flavoprotein, beta polypeptide
MLL-
162.7
16.3
STAT induced STAT inhibitor-2
MLL-t1517
778.6
45.6
Rho GTPase activating protein 4


OTHER-t1517
Rho GTPase activating protein 4
716.0
45.6
MEAN OTHER
MEAN t1517
OTHER-t1517
cathepsin W (lymphopain)
1178.1
162.0
MEAN OTHER
MEAN t1517
OTHER-t821
calcium channel, voltage-dependent, alpha 2/delta subunit 2
123.5
26.4
MEAN OTHER
MEAN t821
OTHER-t821
thyrotropin-releasing hormone
776.7
18.8
MEAN OTHER
MEAN t821
t1517-t821
Rho GTPase activating protein 4
776.5
45.6
t1517-t821
cathepsin W (lymphopain)
1178.1
79.0
OTHER-
homeo box B5
52.0
3.2
MEAN OTHER
MEAN (non Other)
t1517-
Rho GTPase activating protein 4
486.2
45.6
MEAN t1517
MEAN (non t1517)
t1517-
cathepsin W (lymphopain)
1178.1
190.2
MEAN t1517
MEAN (non t1517)
t1517-
hypothetical protein FLJ12442, KIAA0246
2029.4
154.2
MEAN t1517
MEAN (non t1517)

Figure 12c


t821-
MEAN t821
MEAN (non t821)
180.0
160.0
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
123.5
30.5
calcium channel, voltage-dependent, alpha 2/delta subunit 2
t821-
MEAN t821
MEAN (non t821)
250.0
200.0
150.0
100.0
50.0
0.0
140.2
12.0
core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-related
t821-
MEAN t821
MEAN (non t821)
160.0
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
116.7
52.1
regulator of G-protein signalling 10
MLL-t821
MEAN MLL
MEAN t821
1400.0
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
12.7
776.7
thyrotropin-releasing hormone
t821-
MEAN t821
MEAN (non t821)
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
608.4
5.6
POU domain, class 4, transcription factor 1

Figure 12d

Figure 12e


ALLMLL - ALLT
150.0
100.0
50.0
0.0
110.1
10.4
Mean MLL
Mean T
catenin (cadherin-associated protein), alpha 1 (102kD)
ALLMLL - ALLT
200.0
100.0
0.0
156.9
6.4
Mean MLL
Mean T
catenin (cadherin-associated protein), alpha 1 (102kD
ALLMLL - ALLPH
60.0
40.0
20.0
0.0
46.3
17.9
Mean MLL
Mean PH
SHP2 interacting transmembrane adaptor
ALLMLL - ALLPH
160.0
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
116.5
Mean MLL
Mean PH
Glucocorticoid Receptor, Beta

Figure 12f


ALL814-ALLMLL
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
11.4
Mean MLL
Mean 814
v-myb myeloblastosis viral
oncogene homolog (avian)
ALL814 - ALLT
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
821.6
72.1
Mean 814
Mean T
adenosine deaminase
ALL814-ALLMLL
400.0
300.0
200.0
100.0
0.0
297.3
40.0
Series1
Series2
v-myb avian myeloblastosis viral
oncogene homolog
ALL814 - ALLT
600.0
400.0
200.0
0.0
429.6
67.9
Mean 814
Mean T
small inducible cytokine A3
(homologous to mouse Mip-1a)

Figure 12g


ALLPH-ALLT
Mean PH
Mean T
3600.0
2400.0
1200.0
0.0
2517.6
59.7
T cell receptor beta locus
ALLPH-ALLT
ALL Ph
ALL T
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
826.5
14.4
CD3D antigen
ALL814 - ALLPH
Mean 814
Mean PH
300.0
250.0
200.0
150.0
100.0
50.0
0.0
228.6
66.4
KIAA0867 protein
ALL814 - ALLPH
Mean 814
Mean PH
160.0
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
141.8
58.6
hypothetical protein FLJ12443

Figure 12h


ALLT-
Mean ALLT
Mean ALL nonT
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
828.3
22.9
CD3D antigen, delta polypeptide (TiT3 complex)


ALLPH-
Mean PH
Mean nonPH
400.0
350.0
300.0
250.0
200.0
150.0
100.0
50.0
0.0
255.5
25.4
membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10)


ALLT-
Mean ALLT
Mean nonT
800.0
600.0
400.0
200.0
0.0
709.0
269.6
homolog of yeast long chain polyunsaturated fatty acid elongation enzyme 2


ALLPH-
Mean PH
Mean nonPH
300.0
250.0
200.0
150.0
100.0
50.0
0.0
276.2
114.9
KIAA0870 protein

Figure 12i


ALLMLL-
Mean MLL
Mean nonMLL
connective tissue growth factor
ALLMLL-
Mean MLL
Mean nonMLL
very low density lipoprotein receptor
ALL814-
Mean 814
Mean non814
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
ALL814-
Mean 814
Mean non814
annexin A5

Figure 13a




accuracy
1.00
0.98
0.96
0.94
0.92
0.90
0.88
0.86
0.84
0.82
0.80
golub
diffgenes
confidence
1.00
0.80
0.60
0.40
0.20
0.00
golub
diffgenes

Figure 13b

Figure 14



Figure 15


t(15;17), M3/M3v
t(8;21), M2
inv(16), M4eo
Principal Component 1: 46.85% var.
Principal Component 2: 20.53% var.
inv(16), AML M4eo
t(8;21), AML M2
t(15;17), AML M3/M3v



Figure 16



Figure 17

Figure 18


M3/t(15;17)
M3v/t(15;17)
Principal Component 1: 70.66% var.
971.218
2,258.006
3,544.794
4,831.582
6,118.37
Principal Component 2: 11.65% var.
374.927
-280.72
-936.368
-1,592.015
-2,247.663

Figure 19


CD13
r=0.706
p=0.001
CD34
r=0.636
p=0.003
CD15
r=0.530
p=0.016
CD33
r=0.476
p=0.034
CD45
r=0.550
p=0.015
CD7
r=0.478
p=0.033
Average fluorescence intensity by microarray analysis
Mean fluorescence intensity by flow cytometry

Figure 20


a) Karyotype
b) FISH
c) RT -PCR
d) Cytomorphology
inv (16)
t(8;21)
t(15;17)
t(11q23)
M4eo
M2
M3
M3v
M5a

Figure 21





Figure 22


BM
t(15;17)
AML
t(11q23)
inv(16)
t(8;21)
EPOR
LEF1
SGP28
CTSE
LIG1
GENX-3414
IL18RAP
SYNE-2
unknown cDNA
CDKL2
PCYT1B
H2AFN
HOXA10
DKFZP586N1922
MEIS1
CSPG2
LILRB2
FCER2
SECTM1
unknown cDNA
LENG4
PIG8
KRT18
SSTR4
LOC56928
B3GAT3
CLTB
ADD2
APOC2
PGLYRP
HK3
CAMP
TRH
CLU
FLJ12442
SNL
SERPING1
GNA15
DF

Figure 23

219033_at, FLJ21308, ALL t(4;11) vs. all other



Figure 24

2274407_at, ALL t(4;11) vs. all others



Figure 25


239214_at, ALL t(4;11) vs. all others
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 26

221969_at, PAX5, ALL t(4;11) vs. AML t(15;17)



Figure 27

225653_at, ALL t(4;11) vs. AML inv(16)



Figure 28


221969_at, ALL t(4;11) vs. AML MLL
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 29


210045_at, IDH2, ALL t(4;11) vs. CLL
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 30

221969_at, PAX5, ALL t(4;11) vs. CML



Figure 31

201828_x_at, CXX1, ALL t(4;11) vs. normal BM



Figure 32

210045_at, IDH2, ALL t(4;11) vs. ALL t(8;14)



Figure 33


237431_at, ALL t(4;11) vs. ALL B not Ph
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 34

204069_at, MEIS1, ALL t(4;11) vs. ALL Ph



Figure 35


221969_at, PAX5, ALL t(4;11) vs. T-ALL
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 36

201828_x_at, CXX1, ALL t(4;11) vs. AML +8



Figure 37

221969_at, PAX5, ALL t(4;11) vs. AML complex



Figure 38

221969_at, PAX5, ALL t(4;11) vs. AML normal



Figure 39


212484_at, MTVR, ALL t(4;11) vs. AML t(8;21)
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 40

38487_at, FLJ12442, AML t(15;17) vs. all others



Figure 41

203948_s_at, MPO, AML t(15;17) vs. all others



Figure 42

204661_at, CDW52, AML t(15;17) vs. AML inv(16)



Figure 43

205624_at, CPA3, AML t(15;17) vs. AML MLL



Figure 44

203949_at, MPO, AML t(15;17) vs. CLL



Figure 45

201029_s_at, MIC2, AML t(15;17) vs. CML

Figure 46



225792_at, AML t(15;17) vs. normal BM



Figure 47

212400_at, AML t(15;17) vs. ALL t(8;14)



Figure 48

205382_s_at, DF, AML t(15;17) vs. ALL B not Ph



Figure 49

220798_x_at, FLJ11535, AML t(15;17) vs. ALL Ph



Figure 50

203949_at, MPO, AML t(15;17) vs. T-ALL

Figure 51



214450_at, CTSW, AML t(15;17) vs. AML +8



Figure 52

212953_x_at, CALR, AML t(15;17) vs. AML complex

Figure 53



212953_x_at, CALR, AML t(15;17) vs. AML normal



Figure 54


214450_at, CTSW, AML t(15;17) vs. AML t(8;21)
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 55


233555_s_at, AML inv(16) vs. all others
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 56

202016_at, MEST, AML inv(16) vs. all others



Figure 57

200951_s_at, CCND2, AML inv(16) vs. AML MLL



Figure 58

203949_at, MPO, AML inv(16) vs. CLL



Figure 59

201029_s_at, MIC2, AML inv(16) vs. CML



Figure 60



225792_at, AML inv(16) vs. normales KM

Figure 61

214558_at, GPR12, AML inv(16) vs. ALL t(8;14)



Figure 62

205382_s_at, DF, AML inv(16) vs. ALL B not Ph



Figure 63

231310_at, AML inv(16) vs. ALL Ph



Figure 64

203949_at, MPO, AML inv(16) vs. T-ALL



Figure 65

233138_at, AML inv(16) vs. AML +8



Figure 66

209190_s_at, DIAPH1, AML inv(16) vs. AML complex



Figure 67

201497_x_at, MYH11, AML inv(16) vs. AML complex



Figure 68

200675_at, CD81, AML inv(16) vs. AML complex



Figure 69

209365_s_at, ECM1, AML inv(16) vs. AML normal



Figure 70

97/490



Figure 71

231310_at, AML inv(16) vs. AML normal



Figure 72

233138_at, AML inv(16) vs. AML t(8;21)



Figure 73

201105_at, LGALS1, AML MLL vs. all others



Figure 74

222982_x_at, SLC38A2, AML MLL vs. all others



Figure 75

238856_s_at, AML MLL vs. all others



Figure 76

224838_at, AML MLL vs. CLL



Figure 77

209771_x_at, CD24, AML MLL vs. CML



Figure 78


225792_at, AML MLL vs. normal BM
105/490
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 79

227173_s_at, BACH2, AML MLL vs. ALL t(8;14)



Figure 80

201482_at, QSCN6, AML MLL vs. ALL B not Ph



Figure 81


234107_s_at, AML MLL vs. ALL Ph
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 82


242292_at, AML MLL vs. T-ALL
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 83

212479_s_at, FLJ13910, AML MLL vs. AML +8



Figure 84

218172_s_at, PRO2577, AML MLL vs. AML +8



Figure 85

200867_at, AML MLL vs. AML +8



Figure 86

202956_at, BIG1, AML MLL vs. AML +8



Figure 87

202746_at, AML MLL vs. AML complex



Figure 88

204951_at, ARHH, AML MLL vs. AML complex



Figure 89

205453_at, HOXB2, AML MLL vs. AML normal



Figure 90

225406_at, TSG, AML MLL vs. AML normal



Figure 91

201105_at, LGALS1, AML MLL vs. AML t(8;21)



Figure 92


239287_at, CLL vs. all others
119/490
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 93

210254_at, CLL vs. CML



Figure 94

204776_at, THBS4, CLL vs. normal BM



Figure 95

202580_x_at, FOXM1, CLL vs. ALL t(8;14)



Figure 96

225927_at, MAP3K1, CLL vs. ALL B not Ph



Figure 97

204663_at, ME3, CLL vs. ALL Ph



Figure 98

201417_at, CLL vs. T-ALL



Figure 99

204215_at, MGC4175, CLL vs. AML +8



Figure 100

222680_s_at, RAMP, CLL vs. AML complex



Figure 101

224838_at, CLL vs. AML normal



Figure 102

205192_at, MAP3K14, CLL vs. AML t(8;21)



Figure 103

205557_at, BPI, CML vs. all others



Figure 104

209772_s_at, CD24, CML vs. all others



Figure 105

227198_at, CML vs. normal BM



Figure 106

231215_at, CML vs. ALL t(8;14)



Figure 107

206440_at, VELI1, CML vs. ALL B not Ph



Figure 108

209619_at, CD74, CML vs. ALL Ph



Figure 109


210254_at, CML vs. T-ALL
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 110

212531_at, LCN2, CML vs. AML +8



Figure 111

212531_at, LCN2, CML vs. AML complex



Figure 112

212531_at, LCN2, CML vs. AML normal



Figure 113

201029_s_at, MIC2, CML vs. AML t(8;21)



Figure 114

227497_at, CML vs. all others



Figure 115

222147_s_at, normal BM vs. ALL t(8;14)



Figure 116


201506_at, TGFBI, normal BM vs. ALL B not Ph
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 117

225792_at, normal BM vs. ALL Ph



Figure 118

231241_at, normal BM vs. T-ALL



Figure 119

231241_at, normal BM vs. AML +8



Figure 120

231241_at, normal BM vs. AML complex



Figure 121

212531_at, LCN2, normal BM vs. AML normal



Figure 122

225792_at, normal BM vs. AML t(8;21)



Figure 123

225277_at, ALL t(8;14) vs. all others



Figure 124

214558_at, GPR12, ALL t(8;14) vs. all others



Figure 125

228211_at, ALL t(8;14) vs. all others



Figure 126

237864_at, ALL t(8;14) vs. all others



Figure 127

231567_s_at, TSP-NY, ALL t(8;14) vs. ALL B not Ph



Figure 128


204663_at, ME3, ALL t(8;14) vs. ALL Ph
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 129

213772_s_at, GGA2, ALL t(8;14) vs. T-ALL



Figure 130

213159_at, KIAA0805, ALL t(8;14) vs. AML +8



Figure 131

40148_at, APBB2, ALL t(8;14) vs. AML complex



Figure 132

212293_at, KIAA0630, ALL t(8;14) vs. AML complex



Figure 133

160/490

40148_at, APBB2, ALL t(8;14) vs. AML normal



Figure 134

40148_at, APBB2, ALL t(8;14) vs. AML t(8;21)



Figure 135

229487_at, ALL B nicht Ph vs. all others



Figure 136


212592_at, ALL B nicht Ph vs. all others
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 137

209197_at, KIAA0080, ALL B not Ph vs. all others



Figure 138

223469_at, MGC10812, ALL B not Ph vs. all others



Figure 139

224739_at, MG61, ALL B not Ph vs. all others



Figure 140

218351_at, FLJ20502, ALL B not Ph vs. all others



Figure 141

220744_s_at, WDR10, ALL B not Ph vs. all others



Figure 142

213582_at, ATP11A, ALL B not Ph vs. all others



Figure 143

219615_s_at, KCNK5, ALL B not Ph vs. all others



Figure 144

202123_s_at, ABL1, ALL B not Ph vs. ALL Ph



Figure 145

242292_at, ALL B not Ph vs. T-ALL



Figure 146

208248_x_at, APLP2, ALL B not Ph vs. AML +8



Figure 147

218168_s_at, CABC1, ALL B not Ph vs. AML complex



Figure 148

221969_at, PAX5, ALL B not Ph vs. AML normal



Figure 149

202382_s_at, GNPI, ALL B not Ph vs. AML t(8;21)



Figure 150

227998_at, MGC17528, ALL Ph vs. all others



Figure 151

221969_at, PAX5, ALL Ph vs. T-ALL



Figure 152

234107_s_at, ALL Ph vs. AML +8



Figure 153

214641_s_at, HOXA9, ALL Ph vs. AML complex



Figure 154

214641_s_at, HOXA9, ALL Ph vs. AML normal



Figure 155

212013_at, D2S448, ALL Ph vs. AML normal



Figure 156

228827_at, ALL Ph vs. AML t(8;21)



Figure 157


209604_s_at, GATA3, T-ALL vs. all others
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 158

233589_x_at, T-ALL vs. all others



Figure 159

233589_x_at, T-ALL vs. AML +8



Figure 160

207543_s_at, P4HA1, T-ALL vs. AML complex



Figure 161


230292_at, T-ALL vs. AML normal
188/490
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 162

202479_s_at, GS3955, T-ALL vs. AML normal



Figure 163

242292_at, T-ALL vs. AML t(8;21)



Figure 164

226165_at, E2F5, AML +8 vs. all others



Figure 165

212586_at, ARTS-1, AML +8 vs. AML complex



Figure 166

226545_at, AML +8 vs. AML complex



Figure 167

222166_at, AML +8 vs. AML complex



Figure 168

210715_s_at, SPINT2, AML +8 vs. AML complex



Figure 169

217979_at, NET-6, AML +8 vs. AML complex



Figure 170

201548_s_at, PLU-1, AML +8 vs. AML complex



Figure 171

212251_at, AML +8 vs. AML normal



Figure 172

228827_at, AML +8 vs. AML t(8;21)



Figure 173

200608_s_at, RAD21, AML complex vs. all others



Figure 174


219793_at, SNX16, AML complex vs. all others
AML t(8;21)
AML normal
AML complex
AML +8
T-ALL
ALL Ph
ALL B not Ph
ALL t(8;14)
Normal BM
CML
CLL
AML MLL
AML inv(16)
AML t(15;17)
ALL t(4;11)

Figure 175

209523_at, AML complex vs. all others



Figure 176

200093_s_at - HG-U133B, HINT1, AML complex vs. AML normal



Figure 177

201922_at, YR-29, AML complex vs. AML normal



Figure 178

239791_at, HOXB6, AML complex vs. AML normal



Figure 179

200608_s_at, RAD21, AML complex vs. AML normal



Figure 180

211950_at, RBAF600, AML complex vs. AML normal



Figure 181

228827_at, AML complex vs. AML t(8;21)



Figure 182

204249_s_at, LMO2, AML complex vs. AML t(8;21)



Figure 183

236892_s_at, HOXB6, AML normal vs. all others



Figure 184

205366_s_at, HOXB6, AML normal vs. All others



Figure 185

228827_at, AML normal vs. AML t(8;21)



Figure 186

205529_s_at, CBFA2T1, AML t(8;21) vs. all others



Figure 187

201998_at, SIAT1, CLL



Figure 188

204150_at, STAB1, AML t(15;17)



Figure 189

204511_at, KIAA0793, CLL



Figure 190

207819_s_at, ABCB4, CLL



Figure 191

205805_s_at, ROR1, CLL



Figure 192

208091_s_at, DKFZP564K0822, CLL



Figure 193

208456_s_at, RRAS2, CLL

Figure 194



209061_at, NCOA3, CLL



Figure 195

209374_s_at, IGHM, CLL



Figure 196

38487_at, FLJ12442, AML t(15;17)



Figure 197

201162_at, IGFBP7, CLL



Figure 198

201163_s_at, IGFBP7, CLL



Figure 199

202095_s_at, BIRC5, CLL

Figure 200



201362_at, NS1-BP, CML



Figure 201

203074_at, ANXA8, AML t(15;17)



Figure 202

201496_x_at, MYH11, AML inv(16)



Figure 203

205528_s_at, CBFA2T1, AML t(8;21)



Figure 204

201497_x_at, MYH11, AML inv(16)



Figure 205

205529_s_at, CBFA2T1, AML t(8;21)



Figure 206

206940_s_at, POU4F1, AML t(8;21)



Figure 207

212285_s_at, AGRN, AML t(15;17)



Figure 208

209616_s_at, CES1, AML MLL



Figure 209

213539_at, CD3D, T-ALL



Figure 210

214450_at, CTSW, AML t(15;17)

Figure 211



218223_s_at, LOC51177, CML



Figure 212

210997_at, HGF, AML t(15;17)



Figure 213

209101_at, CTGF, ALL t(4;11), ALL Ph, T-ALL



Figure 214

215925_s_at, ALL t(4;11)



Figure 215

239393_at, ALL t(4;11)



Figure 216

239791_at, HOXB6, AML normal, AML +8



Figure 217

240581_at, ALL t(4;11)



Figure 218

241464_s_at, AML MLL, AML normal, AML +8, AML complex



Figure 219

241525_at, AML inv(16)



Figure 220

243362_s_at, LEF1, ALL, CLL



Figure 221

36566_at, CTNS, T-ALL



Figure 222

38487_at, FLJ12442, AML t(15;17)



Figure 223

224794_s_at, LOC51148, AML t(15;17)



Figure 224

228904_at, AML normal, AML +8, AML complex

Figure 225



224520_s_at, MGC13168, ALL t(8;14)



Figure 226

226496_at, ALL, CLL

Figure 227



222166_at, AML +8



Figure 228

225660_at, SEMA6A, ALL B not Ph, ALL Ph



Figure 229

228827_at, AML t(8;21)



Figure 230

236301_at, CLL



Figure 231

236892_s_at, HOXB6, AML normal, AML +8, AML complex



Figure 232

239214_at, ALL t(4;11)



Figure 233


219033_at, FLJ21308, ALL t(4;11) vs. all other
File: ::/ALL.txt.nopa
Gen: 219033_at
100%= 4888.6
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 234


210045_at, IDH2, ALL t(4;11) vs. ALL t(8;14)
File: ../ALL.txt.nopa
Gen: 210045_at
100%= 752.2
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 235

237431_at, ALL t(4;11) vs. ALL B not Ph



Figure 236


204069_at, MEIS1, ALL t(4;11) vs. ALL Ph
File: ../ALL.txt nopa
Gen: 204069_at
100%= 2359.3
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 237

221969_at, PAX5, ALL t(4;11) vs. T-ALL



Figure 238


228211_at, ALL t(8;14) vs. all other
File: ../ALL.txt.nopa
Gen: 228211_at
100%= 208
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 239


202249_s_at, H326, ALL t(8;14) vs. all other
File: ../ALL.txt.nopa
Gen: 202249_s_at
100%= 403.1
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 240


218836_at, FLJ22638, ALL t(8;14) vs. all other
File: ../ALL.txt.nopa
Gen: 218836_at
100%= 507.6
1
2
3
4
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 241


231567_s_at, TSP-NY, ALL t(8;14) vs. ALL B not Ph
File: ../ALL.txt.nopa
Gen: 231567_s_at
100%= 457.6
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 242


204663_at, ME3, ALL t(8;14) vs. ALL Ph
File: ../ALL.txt.nopa
Gen: 204663_at
100%= 1359.8
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 243


213772_s_at, GGA2, ALL t(8;14) vs. T-ALL
File: ..:/ALL.txt.nopa
Gen: 213772_s_at
100%= 333.4
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 244


219358_s_at, CENTA2, ALL B not Ph vs. all other
File: ../ALL.txt.nopa
Gen: 219358_s_at
100%= 242.6
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 245


220744_s_at, WDR10, ALL B not Ph vs. all other
File: ../ALL.txt.nopa
Gen: 220744_s_at
100%= 366.5
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 246


226646_at, KLF2, ALL B not Ph vs. all other
File: ../ALL.txt.nopa
Gen: 226646_at
100%= 878
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 247


202123_s_at, ABL1, ALL B not Ph vs. ALL Ph
File: ../ALL.txt.nopa
Gen: 202123_s_at
100%= 1739.4
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 248

242292_at, ALL B not Ph vs. T-ALL



Figure 249

224833_at, ETS1, ALL Ph vs. all other



Figure 250


221969_at, PAX5, ALL Ph vs. T-ALL
File: ../ALL.txt.hopa
Gen: 221969_at
100%= 4807.2
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 251


221969_at, PAX5, T-ALL vs. all other
File: ../ALL.txt hopa
Gen: 221969_at
100%= 4807.2
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 252


219033_at, FLJ21308, ALL t(4;11) vs. all other
File: ../ALL.txt.nopa
Gen: 219033_at
100%= 4888.6
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 253


210045_at, IDH2, ALL t(4;11) vs. ALL t(8;14)
File: ../ALL.txt.nopa
Gen: 210045_at
100%= 752.2
1
2
3
4
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 254


237431_at, ALL t(4;11) vs. ALL B not Ph
File: ../ALL.txt.nopa
Gen: 237431_at
100%= 174.6
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 255


204069_at, MEIS1, ALL t(4;11) vs. ALL Ph
File: ../ALL.txt nopa
Gen: 204069_at
100%= 2359.3
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 256


221969_at, PAX5, ALL t(4;11) vs. T-ALL
File: ..:/ALL.txt nopa
Gen: 221969_at
100%= 4807.2
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 257

228211_at, ALL t(8;14) vs. all other



Figure 258


202249_s_at, H326, ALL t(8;14) vs. all other
File: ../ALL.txt.nopa
Gen: 202249_s_at
100%= 403.1
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 259

218836_at, FLJ22638, ALL t(8;14) vs. all other



Figure 260


231567_s_at, TSP-NY, ALL t(8;14) vs. ALL B not Ph
File: ..:/ALL.txt.nopa
Gen: 231567_s_at
100%= 457.6
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 261


204663_at, ME3, ALL t(8;14) vs. ALL Ph
File: ../ALL.txt.nopa
Gen: 204663_at
100%= 1359.8
1
2
3
4
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 262


213772_s_at, GGA2, ALL t(8;14) vs. T-ALL
File: ../ALL.txt.nopa
Gen: 213772_s_at
100%= 333.4
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 263


219358_s_at, CENTA2, ALL B not Ph vs. all other
File: ../ALL.txt.nopa
Gen: 219358_s_at
100%= 242.6
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 264


220744_s_at, WDR10, ALL B not Ph vs. all other
File: ..:/ALL.txt.nopa
Gen: 220744_s_at
100%= 366.5
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 265


226646_at, KLF2, ALL B not Ph vs. all other
File: ../ALL.txt.nopa
Gen: 226646_at
100%= 878
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 266


202123_s_at, ABL1, ALL B not Ph vs. ALL Ph
File: ../ALL.txt.nopa
Gen: 202123_s_at
100%= 1739.4
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 267


242292_at, ALL B not Ph vs. T-ALL
File: ../ALL.txt.nopa
Gen: 242292_at
100%= 112.1
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 268

224833_at, ETS1, ALL Ph vs. all other



Figure 269


221969_at, PAX5, ALL Ph vs. T-ALL
File: ../ALL.txt.nopa
Gen: 221969_at
100%= 4807.2
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 270


221969_at, PAX5, T-ALL vs. all other
File: ..:/ALL.txt.hopa
Gen: 221969_at
100%= 4807.2
t(4;11)
t(8;14)
ALLBnotPh
ALLPh
T-ALL

Figure 271

218549_s_at, LOC51115, trisomy 8 vs. other aberrant



Figure 272

235647_at, trisomy 8 vs. all other AML



Figure 273

231981_at, trisomy 8 vs. all other AML



Figure 274

229848_at, ZNF10, trisomy 8 vs. ather aberrant



Figure 275

212586_at, ARTS-1, trisomy 8 vs. complex



Figure 276

226545_at, trisomy 8 vs. complex



Figure 277

222166_at, trisomy 8 vs. complex



Figure 278

210715_s_at, SPINT2, trisomy 8 vs. complex



Figure 279

217979_at, NET-6, trisomy 8 vs. complex



Figure 280



201548_s_at, PLU-1, trisomy 8 vs. complex

Figure 281

212251_at, trisomy 8 vs. normal

Figure 282



228827_at, trisomy 8 vs. t(8;21)



Figure 283

214450_at, CTSW, trisomy 8 vs. t(15;17)



Figure 284

233138_at, trisomy 8 vs. inv(16)



Figure 285

212479_s_at, FLJ13910, trisomy 8 vs. MLL



Figure 286

218172_s_at, PRO2577, trisomy 8 vs. MLL



Figure 287

200867_at, trisomy 8 vs. MLL



Figure 288

202956_at, BIG1, trisomy 8 vs. MLL



Figure 289

236648_at, other aberrant vs. all other AML



Figure 290

228660_x_at, SEMA4F, other aberrant vs. all other AML



Figure 291

211819_s_at, SH3D5, other aberrant vs. complex

Figure 292



233328_x_at, other aberrant vs. complex



Figure 293

229003_x_at, other aberrant vs. complex



Figure 294

233328_x_at, other aberrant vs. normal



Figure 295

322/490

213725_x_at, other aberrant vs. normal



Figure 296

221770_at, RPE, other aberrant vs. t(8;21)



Figure 297

213716_s_at, SECTM1, other aberrant vs. t(15;17)



Figure 298

227224_at, other aberrant vs. inv(16)



Figure 299

232125_at, other aberrant vs. MLL



Figure 300

200608_s_at, RAD21, complex vs. all other AML



Figure 301

209085_x_at, RFC1, complex vs. all other AML

Figure 302



201922_at, YR-29, complex vs. normal

Figure 303



239791_at, HOXB6, complex vs. normal



Figure 304

200608_s_at, RAD21, complex vs. normal



Figure 305

211950_at, RBAF600, complex vs. normal



Figure 306


228827_at, complex vs. t(8;21)
MLL
inv(16)
t(15;17)
t(8;21)
normal
complex
other aberrant
trisomy 8
File: ../AML.txt.nopa
Gen: 228827_at
100%= 1683.8

Figure 307

204249_s_at, LMO2, complex vs. t(8;21)



Figure 308

212953_x_at, CALR, complex vs. t(15;17)



Figure 309

209190_s_at, DIAPH1, complex vs. inv(16)



Figure 310

201497_x_at, MYH11, complex vs. inv(16)



Figure 311

200675_at, CD81, complex vs. inv(16)



Figure 312

202746_at, complex vs. MLL



Figure 313


204951_at, ARHH, complex vs. MLL
MLL
inv(16)
t(15;17)
t(8;21)
normal
complex
other aberrant
trisomy 8
File: ../AML.txt.nopa
Gen: 204951_at
100%= 2713

Figure 314

236892_s_at, HOXB6, normal vs. all other AML



Figure 315

228904_at, normal vs. all other AML



Figure 316

200679_x_at, HMG1, normal vs. all other AML



Figure 317

225326_at, KIAA1311, normal vs. all other AML



Figure 318

228827_at, normal vs. t(8;21)



Figure 319

212953_x_at, CALR, normal vs. t(15;17)



Figure 320


209365_s_at, ECM1, normal vs. inv(16)
MLL
inv(16)
t(15;17)
t(8;21)
normal
complex
other aberrant
trisomy 8
File: ../AML.txt.nopa
Gen: 209365_s_at
100%= 2319

Figure 321

348/490

231310_at, normal vs. inv(16)



Figure 322

202370_s_at, CBFB, normal vs. inv(16)



Figure 323

205453_at, HOXB2, normal vs. MLL



Figure 324

225406_at, TSG, normal vs. MLL



Figure 325

352/490

222464_at, C15orf15, normal vs. MLL



Figure 326

205529_s_at, CBFA2T1, t(8;21) vs. all other AML



Figure 327

214450_at, CTSW, t(8;21) vs. t(15;17)



Figure 328

355/490



Figure 329

201105_at, LGALS1, t(8;21) vs. MLL



Figure 330

203948_s_at, MPO, t(15;17) vs. all other AML



Figure 331

204661_at, CDW52, t(15;17) vs. inv(16)



Figure 332

205624_at, CPA3, t(15;17) vs. MLL



Figure 333

360/490

201497_x_at, MYH11, inv(16) vs. all other AML



Figure 334

200951_s_at, CCND2, inv(16) vs. MLL



Figure 335

228083_at, MLL vs. all other AML

Figure 336



635_s_at, PPP2R5B, other low



Figure 337

34210_at, CDW52, AML t(15;17) low



Figure 338

38487_at, FLJ12442, AML t(15;17) high



Figure 339

200675_at, CD81, AML inv(16) low



Figure 340

201137_s_at, HLA-DPB1, AML t(15;17) low



Figure 341


201425_at, ALDH2, AML t(8;21) low
MLL
inv(16)
t(15;17)
t(8;21)
normal
complex
other aberrant
trisomy 8

Figure 342

201496_x_at, MYH11, AML inv(16) high



Figure 343

201497_x_at, MYH11, AML inv(16) high



Figure 344

201596_x_at, KRT18, AML t(8;21) low



Figure 345

202085_at, TJP2, AML inv(16) low



Figure 346

202619_s_at, PLOD2, AML MLL low



Figure 347

202718_at, IGFBP2, AML t(15;17) high



Figure 348

202746_at, AML MLL low



Figure 349

203074_at, ANXA8, AML t(15;17) high



Figure 350

203092_at, TIMM44, AML inv(16) low



Figure 351

203151_at, MAP1A, AML t(8;21) low



Figure 352

205528_s_at, CBFA2T1, AML t(8;21) high



Figure 353

205529_s_at, CBFA2T1, AML t(8;21) high



Figure 354

204425_at, ARHGAP4, AML t(15;17) low



Figure 355

205366_s_at, HOXB6, AML t(8;21) low, AML t(15;17) low, AML inv(16) low, AML MLL low



Figure 356

205380_at, PDZK1, other high



Figure 357

205472_s_at, DACH, AML MLL high



Figure 358

225330_at, AML inv(16) low



Figure 359

228660_x_at, SEMA4F, other high



Figure 360

206761_at, TACTILE, AML MLL low



Figure 361

206940_s_at, POU4F1, AML t(8;21) high



Figure 362

211341_at, POU4F1, AML t(8;21) high



Figure 363

212850_s_at, LRP4, AML inv(16) high



Figure 364

222166_at, AML +8 low



Figure 365

222335_at, AML MLL low



Figure 366

223318_s_at, MGC10974, AML complex low



Figure 367

228827_at, AML t(8;21) high



Figure 368

228904_at, AML t(8;21) low, AML t(15;17) low, AML inv(16) low, AML MLL low



Figure 369


231277_x_at, AML complex low
MLL
inv(16)
t(15;17)
t(8;21)
normal
complex
other aberrant
trisomy 8
File: ./AML.txt.nops
Gen: 231277_x_at
100%= 420.6

Figure 370


203787_at, SSBP2, tri 12 vs. all others
File: ..:/CLL.txt.nopa
Gen: 203787_at
100%= 330
1
2
3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
+12
11q-
13q-
17p-
normal

Figure 371


240785_at, tri 12 vs. all others
File: ..:/CLL.txt.nopa
Gen: 240785_at
100%= 108
+12
11q-
13q-
17p-
normal

Figure 372


219234_x_at, FLJ23142, tri 12 vs. all others
File: ../CLL.txt.nopa
Gen: 219234_x_at
100%= 72.8
+12
11q-
13q-
17p-
normal

Figure 373


233106_at, tri 12 vs. 11q-
File: ../CLL.txt.nopa
Gen: 233106_at
100%= 54.3
+12
11q-
13q-
17p-
normal

Figure 374


241930_x_at, tri 12 vs. 13q-
File: ../CLL.txt.mopa
Gen: 241930_x_at
100%= 63.5
+12
11q-
13q-
17p-
normal

Figure 375


240801_at, C21orf37, tri 12 vs. 17p-
File: ../CLL.txt.nopa
Gen: 240801_at
100%= 40.8
+12
11q-
13q-
17p-
normal

Figure 376


204227_s_at, TK2, tri 12 vs. normal
File: ../CLL.txt.nopa
Gen: 204227_s_at
100%= 378.3
+12
11q-
13q-
17p-
normal

Figure 377


218089_at, C20orf4, 11q- vs. all others
File: ..:/CLL.txt.nopa
Gen: 218089_at
100%= 713.3
+12
11q-
13q-
17p-
normal

Figure 378


219846_at, FLJ23040, 11q- vs. 13q-
File: ../CLL.txt.nopa
Gen: 219846_at
100%= 157.3

Figure 379


203910_at, PARG1, 11q- vs. 17p-
File: ..:/CLL.txt.nopa
Gen: 203910_at
100%= 165.8
+12
11q-
13q-
17p-
normal

Figure 380


227988_s_at, CHAC, 11q- vs. normal
File: ../CLL.txt.nopa
Gen: 227988_s_at
100%= 281.4
+12
11q-
13q-
17p-
normal

Figure 381

209561_at, THBS3, 13q- vs. all others



Figure 382


212346_s_at, 13q- vs. all others
File: ::/CLL.txt.mopa
Gen: 212346_s_at
100%= 402.1
+12
11q-
13q-
17p-
normal

Figure 383

214693_x_at, DJ328E19.C1.1, 13q- vs. all others



Figure 384


224254_x_at, 13q- vs. Rest
File: ../CLL.txt.nopa
Gen: 224254_x_at
100%= 258.7
+12
11q-
13q-
17p-
normal

Figure 385


206178_at, PLA2G5, 13q- vs. all others
File: ../CLL.txt.nopa
Gen: 206178_at
100%= 164.8
+12
11q-
13q-
17p-
normal

Figure 386


205074_at, SLC22A5, 13q- vs. 17p-
File: ../CLL.txt.nopa
Gen: 205074_at
100%= 221.3
+12
11q-
13q-
17p-
normal

Figure 387


233137_at, 13q- vs. normal
File: ../CLL.txt.nopa
Gen: 233137_at
100%= 289.3
+12
11q-
13q-
17p-
normal

Figure 388


239279_at, 13q- vs. normal
File: ../CLL.txt.nopa
Gen: 239279_at
100%= 75.1
+12
11q-
13q-
17p-
normal

Figure 389


217920_at, 13q- vs. normal
File: ../CLL.txt.nopa
Gen: 217920_at
100%= 167.1
+12
11q-
13q-
17p-
normal

Figure 390

214693_x_at, DJ328E19.C1.1, 13q- vs. normal



Figure 391


229711_s_at, MGC5370, 13q- vs. normal
File: ../CLL.txt.nopa
Gen: 229711_s_at
100%= 774.5
+12
11q-
13q-
17p-
normal

Figure 392


210807_s_at, SLC16A7, 17p- vs. all others
File: ../CLL.txt.nopa
Gen: 210807_s_at
100%= 211.9
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
+12
11q-
13q-
17p-
normal

Figure 393


227047_x_at, KIAA1538, 17p- vs. all others
File: ../CLL.txt.nopa
Gen: 227047_x_at
100%= 466.3
+12
11q-
13q-
17p-
normal

Figure 394


243493_at, 17p- vs. all others
File: ../CLL.txt.nopa
Gen: 243493_at
100%= 149.7
+12
11q-
13q-
17p-
normal

Figure 395


239263_at, 17p- vs. normal
File: ../CLL.txt.nopa
Gen: 239263_at
100%= 125.6
+12
11q-
13q-
17p-
normal

Figure 396


217920_at, normal vs. all others
File: ../CLL.txt.nopa
Gen: 217920_at
100%= 167.1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
+12
11q-
13q-
17p-
normal

Figure 397


239279_at, normal vs. all others
File: ../CLL.txt.nopa
Gen: 239279_at
100%= 75.1
+12
11q-
13q-
17p-
normal

Figure 398


231945_at, KIAA1275, normal vs. all others
File: ../CLL.txt.nopa
Gen: 231945_at
100%= 152.6
1 2 3 4
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
+12
11q-
13q-
17p-
normal

Figure 399


240113_at, normal vs. all other
File: ../CLL.txt.nopa
Gen: 240113_at
100%= 162.3
+12
11q-
13q-
17p-
normal

Figure 400


219641_at, FLJ10103, normal vs. all others
File: ../CLL.txt.nopa
Gen: 219641_at
100%= 178
+12
11q-
13q-
17p-
normal

Figure 401


219457_s_at, RIN3, normal vs. all others
File: ../CLL.txt.nopa
Gen: 219457_s_at
100%= 1078.1
+12
11q-
13q-
17p-
normal

Figure 402


228408_s_at, FLJ10498, normal vs. all others
File: ../CLL.txt.nopa
Gen: 228408_s_at
100%= 427.3
+12
11q-
13q-
17p-
normal

Figure 403


235052_at, normal vs. all others
File: ../CLL.txt.nopa
Gen: 235052_at
100%= 87.1
+12
11q-
13q-
17p-
normal

Figure 404

219013_at, FLJ21634, ALL vs. all others



Figure 405

243362_s_at, LEF1, ALL vs. all others



Figure 406

204215_at, MGC4175, ALL vs. AML



Figure 407

225927_at, MAP3K1, ALL vs. CLL



Figure 408

205557_at, BPI, ALL vs. CML



Figure 409

2232280_x_at, MS4A6A, ALL vs. normal BM



Figure 410

224356_x_at, MS4A6A, ALL vs. normal BM



Figure 411

218916_at, FLJ23436, ALL vs. normal BM



Figure 412

221969_at, PAX5, AML vs. all others



Figure 413

206398_s_at, CD19, AML vs. Rest



Figure 414

223514_at, CARD11, AML vs. CLL



Figure 415

207802_at, SGP28, AML vs. CML



Figure 416

209772_s_at, CD24, AML vs. CML



Figure 417

206676_at, CEACAM8, AML vs. CML



Figure 418

203936_s_at, MMP9, AML vs. CML



Figure 419

201029_s_at, MIC2, AML vs. CML



Figure 420

223894_s_at, FTS, AML vs. CML



Figure 421

207269_at, DEFA4, AML vs. CML



Figure 422

202018_s_at, LTF, AML vs. normal BM



Figure 423

239287_at, CLL vs. all others



Figure 424

210254_at, CLL vs. CML



Figure 425

210613_s_at, SYNGR1, CLL vs. normal BM



Figure 426

205557_at, BPI, CML vs. all others



Figure 427

209772_s_at, CD24, CML vs. all others



Figure 428

227198_at, CML vs. normal BM



Figure 429

231241_at, normal BM vs. all others



Figure 430

227497_at, normal BM vs. all others



Figure 431

202580_x_at, FOXM1, CLL



Figure 432

202709_at, FMOD, CLL



Figure 433

202503_s_at, KIAA0101, CLL



Figure 434

204882_at, KIAA0053, CLL



Figure 435

218090_s_at, CLL



Figure 436

211352_s_at, NCOA3, CLL



Figure 437

217950_at, NOSIP, CLL



Figure 438

228471_at, CLL



Figure 439

226147_s_at, CLL



Figure 440

239287_at, CLL



Figure 441

205051_s_at, KIT, AML



Figure 442

214761_at, OAZ, ALL



Figure 443

231854_at, CML



Figure 444

211404_s_at, APLP2, AML



Figure 445

205382_s_at, DF, AML high



Figure 446

205599_at, TRAF1, CML absent, CLL high



Figure 447

210948_s_at, LEF1, lymphatic high



Figure 448

206398_s_at, CD19, lymphatic high



Figure 449

229487_at, ALL high



Figure 450

206255_at, BLK, lymphatic high



Figure 451

243362_s_at, LEF1, ALL high



Figure 452

205049_s_at, CD79A, lymphatic high



Figure 453

205382_s_at, DF, AML high



Figure 454

210487_at, DNTT, ALL high



Figure 455

218516_s_at, FLJ20421, normal BM absent



Figure 456

218916_at, FLJ23436, normal BM absent



Figure 457

219753_at, STAG3, ALL high



Figure 458

221969_at, PAX5, lymphatic high



Figure 459

223703_at, CDA017, myeloid and BM high



Figure 460

243363_at, LEF1, lymphatic high



Figure 461

41577_at, PPP1R16B, CML low



Figure 462

229790_at, TERF2, CML, BM low



Figure 463

231736_x_at, MGST1, myeloid and BM high



Figure 464

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number
WO 2003/039443 A3

(51) International Patent Classification[7]: C12Q 1/68

(21) International Application Number: PCT/EP2002/012303

(22) International Filing Date: 4 November 2002 (04.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01126244.1 5 November 2001 (05.11.2001) EP
02009758.0 30 April 2002 (30.04.2002) EP

(71) Applicants (*for all designated States except US*): DEUTSCHES KREBSFORSCHUNGSZENTRUM [DE/DE]; Im Neuenheimer Feld 280, 69120 Heidelberg (DE). LUDWIG-MAXIMILIANS -UNIVERSITÄT [DE/DE]; Geschwister-Scholl-Platz 1, 80539 Munich (DE).

(71) Applicants and
(72) Inventors: **HAFERLACH, Torsten** [DE/DE]; Springerstrasse 8, 81477 Munich (DE). **SCHOCH, Claudia** [DE/DE]; Springerstrasse 8, 81477 Munich (DE). **KERN, Wolfgang** [DE/DE]; Hanfelder Strasse 101, 82319 Starnberg (DE).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **KOHLMANN, Alexander** [DE/DE]; Schwarzstrasse 14, 92318 Neumarkt (DE). **SCHNITTGER, Susanne** [DE/DE]; Saalburgstrasse 2a, 81375 Munich (DE). **DUGAS, Martin** [DE/DE]; Am Heidebruch 6, 81377 Munich (DE). **EILS, Roland** [DE/DE]; Strahlenberger Strasse 26, 69198 Schriesheim (DE). **BRORS, Benedikt** [DE/DE]; Im Linsenbühl 42, 69221 Dossenheim (DE). **MERGENTHALER, Susanne** [DE/DE]; Grubmühlerfeldstr. 19, 82131 Gauting (DE).

(74) Agent: **VOSSIUS & PARTNER**; Siebertstrasse 4, 81675 Munich (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report: 19 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL GENETIC MARKERS FOR LEUKEMIAS

(57) Abstract: The present invention is related to methods for detecting leukemia cells by determing the expression profile of a group of markers. In particular, the type or subtype of leukemia cells in a sample is determined. Further, uses of the group of markers is discloses and compositions comprising these markers.

WO 2003/039443 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/12303

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, SCISEARCH, EMBASE, CHEM ABS Data, WPI Data, PAJ, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GOLUB T R ET AL: "Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 531-537, XP002207658 ISSN: 0036-8075 cited in the application the whole document	1-3, 9-11, 16-42, 44,45, 48,53-55

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
4 December 2003	12. 03. 2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hagenmaier, S

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	-& "CAMP: "Microarray Gene Expression Data""[Online] XP002263385 Retrieved from the Internet: <URL:http://genome-www5.stanford.edu/cgi-bin/source/sourceResult> [retrieved on 2003-11-24] the whole document -----	
Y	EP 1 043 676 A (WHITEHEAD BIOMEDICAL INST) 11 October 2000 (2000-10-11) the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
Y	ALIZADEH A A ET AL: "DISTINCT TYPES OF DIFFUSE LARGE B-CELL LYMPHOMA IDENTIFIED BY GENE EXPRESSION PROFILING" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 403, 3 February 2000 (2000-02-03), pages 503-512, XP002943414 ISSN: 0028-0836 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
Y	ALIZADEH A ET AL: "THE LYMPHOCHIP: A SPECIALIZED CDNA MICROARRAY FOR THE GENOMIC-SCALE ANALYSIS OF GENE EXPRESSION IN NORMAL AND MALIGNANT LYMPHOCYTES" COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, BIOLOGICAL LABORATORY, COLD SPRING HARBOR, NY, US, vol. 64, no. 1, 1999, pages 71-78, XP001099007 ISSN: 0091-7451 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
Y	VIRTANEVA K ET AL: "EXPRESSION PROFILING REVEALS FUNDAMENTAL BIOLOGICAL DIFFERENCES IN ACUTE MYELOID LEUKEMIA WITH ISOLATED TRISOMY 8 AND NORMAL CYTOGENETICS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 3, 30 January 2001 (2001-01-30), pages 1124-1129, XP002952627 ISSN: 0027-8424 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96/08508 A (GUDMUNDSSON GUDMUNDUR H ;BOMAN HANS G (SE); GUNNE HANS (SE); AGERB) 21 March 1996 (1996-03-21) the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
Y	AGERBERTH B ET AL: "FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 3 JAN 1995, vol. 92, no. 1, 3 January 1995 (1995-01-03), pages 195-199, XP002263224 ISSN: 0027-8424 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
Y	NAGAOKA I ET AL: "Evaluation of the expression of human CAP18 gene during neutrophil maturation in the bone marrow." JOURNAL OF LEUKOCYTE BIOLOGY. UNITED STATES DEC 1998, vol. 64, no. 6, December 1998 (1998-12), pages 845-852, XP008025075 ISSN: 0741-5400 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
A	MIYAZATO A ET AL: "IDENTIFICATION OF MYELODYSPLASTIC SYNDROME-SPECIFIC GENES BY DNA MICROARRAY ANALYSIS WITH PURIFIED HEMATOPOIETIC STEM CELL FRACTION" BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 98, no. 2, 15 July 2001 (2001-07-15), pages 422-427, XP002952629 ISSN: 0006-4971 the whole document -----	
A	ROSS D T ET AL: "SYSTEMATIC VARIATION IN GENE EXPRESSION PATTERNS IN HUMAN CANCER CELL CEL LINES" NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 24, March 2000 (2000-03), pages 227-235, XP002933374 ISSN: 1061-4036 the whole document -----	

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SORLIE T ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 11 SEP 2001, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869-10874, XP002215483 ISSN: 0027-8424 the whole document -----	
P,Y	SCHOCH CLAUDIA ET AL: "Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 23 JUL 2002, vol. 99, no. 15, 23 July 2002 (2002-07-23), pages 10008-10013, XP002215484 ISSN: 0027-8424 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
P,Y	WO 02/24956 A (DANA FARBER CANCER INST INC ;RAMASWAMY SRIDHAR (US); WHITEHEAD BIO) 28 March 2002 (2002-03-28) the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
P,Y	KOHLMANN A ET AL: "GENE EXPRESSION PROFILES OF DISTINCT AML SUBTYPES IN COMPARISON TO NORMAL BONE MARROW" BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 98, no. 11, PART 1, 16 November 2001 (2001-11-16), page 91A,AN380, XP001108980 ISSN: 0006-4971 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
P,Y	DUGAS M ET AL: "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping." LEUKEMIA: OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K. ENGLAND DEC 2001, vol. 15, no. 12, December 2001 (2001-12), pages 1805-1810, XP002263731 ISSN: 0887-6924 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	YEOH E-J ET AL: "Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling" CANCER CELL, XX, US, vol. 1, no. 2, March 2002 (2002-03), pages 133-143, XP002253604 ISSN: 1535-6108 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
P,Y	TAVOR SIGAL ET AL: "A model for C/EBPalpha-induced differentiation of BCR-ABL+ CML blast cells" BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), page 143a, XP002263225 43rd Annual Meeting of the American Society of Hematology, Part 1;Orlando, Florida, USA; December 07-11, 2001 ISSN: 0006-4971 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
P,A	DATABASE GENESEQ [Online] EBI; 14 August 2002 (2002-08-14), BEAZER-BARCLAY ET AL.: "HUMAN cDNA DIFFERENTIALLY EXPRESSED IN GRANULOCYTIC CELLS" XP002263228 Database accession no. ABK84778 abstract -----	
T	YANG YING-HUA ET AL: "Expression of LL-37/hCAP-18 gene in human leukemia cells." LEUKEMIA RESEARCH, vol. 27, no. 10, October 2003 (2003-10), pages 947-950, XP002263226 ISSN: 0145-2126 (ISSN print) the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55
T	HAFERLACH TORSTEN ET AL: "The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL." BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 523, XP002263227 44th Annual Meeting of the American Society of Hematology;Philadelphia, PA, USA; December 06-10, 2002 ISSN: 0006-4971 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	KOHLMANN ALEXANDER ET AL: "Molecular characterization of acute leukemias by use of microarray technology." GENES, CHROMOSOMES & CANCER. UNITED STATES AUG 2003, vol. 37, no. 4, August 2003 (2003-08), pages 396-405, XP008025253 ISSN: 1045-2257 the whole document -----	1-3, 9-11, 16-42, 44,45, 48,53-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/12303

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [ ] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. [X] Claims Nos.: 1-3, 9-11,16-42,44,45,48,53-55 (all partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [X] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3, 9-11, 16-42, 44, 45, 48, 53-55 (all partially)

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-3, 9-11,16-42,44,45,48,53-55 (all partially)

Claims 1-3, 9-11,16-42,44,45,48,53-55 are directed to methods, kits and compositions which relate to an extremely large number of possible marker groups comprising the CAMP marker. In fact, the claims contain so many possible permutations that a lack of conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been limited to methods, kits and compositions relating to CAMP as such.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-3, 9-11,16-42,44,45,48,53-55 (all partially)

Invention 1:

Methods relating to diagnosis and therapy of leukemia comprising determining the expression profile of a group of markers in a patient sample characterized in that one marker is CAMP; kit comprising a reagent for assessing the expression profile of CAMP; protein or mRNA, cDNA or cRNA corresponding to CAMP for the treatment of leukemia; a composition comprising a group of markers and substances chemically different to the markers characterized in that the group of markers comprise CAMP.

---

2. claims: 1-55 (all partially)

Inventions 2-3309:

Methods relating to diagnosis and therapy of leukemia comprising determining the expression profile of a group of markers in a patient sample characterized in that one marker is SYNE-1B; kit comprising a reagent for assessing the expression profile of SYNE-1B; protein or mRNA, cDNA or cRNA corresponding to SYNE-1B for the treatment of leukemia; a composition comprising a group of markers and substances chemically different to the markers characterized in that the group of markers comprise SYNE-1B.

..ibidem for each marker listed in tables 1-20,25-27,29,30,32,33,35,36,38,39,41,42

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 02/12303

Patent document cited in search report		Publication date	Patent family member(s)			Publication date
EP 1043676	A	11-10-2000	CA	2304876	A1	09-10-2000
			EP	1043676	A2	11-10-2000
			JP	2001017171	A	23-01-2001
			US	2003017481	A1	23-01-2003
			US	6647341	B1	11-11-2003
			US	2003073083	A1	17-04-2003
WO 9608508	A	21-03-1996	AU	3536895	A	29-03-1996
			SE	9403055	A	14-03-1996
			WO	9608508	A1	21-03-1996
WO 0224956	A	28-03-2002	AU	9280201	A	02-04-2002
			EP	1339872	A2	03-09-2003
			WO	0224956	A2	28-03-2002
			US	2002110820	A1	15-08-2002